https://doi.org/10.4081/vl.2025.14166
When lymphedema becomes elephantiasis: a multidisciplinary challenge in a patient with severe obesity and cardiopulmonary comorbidities
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Accepted: 1 September 2025
Published: 30 September 2025
Lymphedema is a progressive condition that can reach an extreme, debilitating stage known as elephantiasis. This case presents a 57-year-old man with stage III by International Society of Lymphology (ISL) lower limb primary lymphedema diagnosed by a lymphoscintigraphy, morbid obesity (BMI >65), obesity hypoventilation syndrome, chronic pulmonary heart disease, and story of prior pulmonary embolism. At admission, high-resolution ultrasound revealed severe subcutaneous thickening, with maximum values exceeding 11 cm. A multidisciplinary inpatient approach was implemented involving vascular surgeons, internists, cardiologist, urologist, pneumologist, dietitians, physiotherapists, and specialized nursing care. Only through the collaboration among all these professional figures it was possible to manage such a complex case. Treatment included high-pressure multilayer compressive bandaging and a Very-Low-Calorie Ketogenic Diet (VLCKD). This led to a significant reduction in subcutaneous thickness (up to 80% in some sites). During three weeks of hospitalization the weight loss was only 7 kg, little but nevertheless relevant, probably due to the total immobility and the poor compliance of the patient. The case underscores the importance of coordinated nutritional, vascular, and medical care in managing complex, end-stage lymphedema.
Downloads
How to Cite

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

